JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Search

10X Genomics Inc (Class A)

Chiusa

SettoreSettore sanitario

17.69 -6.85

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

17.34

Massimo

19.29

Metriche Chiave

By Trading Economics

Entrata

-62M

-27M

Vendite

-24M

149M

Margine di Profitto

-18.437

Dipendenti

1,306

EBITDA

-63M

-16M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-6.14% downside

Dividendi

By Dow Jones

Utili prossimi

12 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

819M

2.5B

Apertura precedente

24.54

Chiusura precedente

17.69

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

10X Genomics Inc (Class A) Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 feb 2026, 23:57 UTC

Utili

Naver Has Record Year Despite Weaker Final Quarter

5 feb 2026, 23:45 UTC

Azioni calde

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5 feb 2026, 22:26 UTC

Utili

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5 feb 2026, 22:00 UTC

Utili

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5 feb 2026, 23:47 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

5 feb 2026, 23:47 UTC

Discorsi di Mercato

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5 feb 2026, 23:43 UTC

Discorsi di Mercato

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5 feb 2026, 23:37 UTC

Discorsi di Mercato

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5 feb 2026, 23:20 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5 feb 2026, 23:11 UTC

Discorsi di Mercato

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5 feb 2026, 23:09 UTC

Utili

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5 feb 2026, 23:08 UTC

Utili

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5 feb 2026, 23:07 UTC

Utili

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5 feb 2026, 23:03 UTC

Discorsi di Mercato
Utili

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5 feb 2026, 23:03 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5 feb 2026, 23:00 UTC

Utili

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5 feb 2026, 23:00 UTC

Utili

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5 feb 2026, 22:59 UTC

Utili

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5 feb 2026, 22:59 UTC

Utili

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5 feb 2026, 22:52 UTC

Utili

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5 feb 2026, 22:45 UTC

Utili

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5 feb 2026, 22:37 UTC

Discorsi di Mercato

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5 feb 2026, 22:11 UTC

Utili

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5 feb 2026, 22:03 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5 feb 2026, 22:01 UTC

Utili

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5 feb 2026, 21:59 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5 feb 2026, 21:51 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5 feb 2026, 21:50 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Basic Materials Roundup: Market Talk

5 feb 2026, 21:49 UTC

Utili

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5 feb 2026, 21:45 UTC

Utili

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Confronto tra pari

Modifica del prezzo

10X Genomics Inc (Class A) Previsione

Obiettivo di Prezzo

By TipRanks

-6.14% in calo

Previsioni per 12 mesi

Media 17.89 USD  -6.14%

Alto 22 USD

Basso 14 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per 10X Genomics Inc (Class A) - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

3

Acquista

8

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

8.32 / 8.63Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

No Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat